MKMwafaq Kmail

Mwafaq Kmail

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mwafaq Kmail has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Natural Medicines Targeting Mitochondrial Dysfunction in Spinocerebellar Ataxia Type 3: A Narrative Review of Cellular and Molecular Events

    by Mwafaq Kmail, Noor Asyikin Suaidi, Jin Han Chin, Lee Wei Lim, Kah Hui Wong

    Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease, is the most common autosomal dominant spinocerebellar ataxia and is characterized by progressive neurodegeneration for which no Food and Drug Administration (FDA)-approved therapeutics are currently available. Mitochondrial dysfunction has emerged as a central pathogenic mechanism in SCA3, making it a promising therapeutic target. This narrative review aims to evaluate the published evidence on the therapeutic potential of natural medicines and their active compounds targeting mitochondrial dysfunction in SCA3. This review summarizes published evidence on the therapeutic potential of natural medicines and their active compounds targeting mitochondrial dysfunction in SCA3 in preclinical studies. The reviewed studies suggest the therapeutic potential of Glycyrrhiza inflata, Codonopsis pilosula, Ginkgo biloba, Poria cocos, Pueraria lobata, Rehmannia glutinosa, Curcuma longa, Hericium erinaceus, Astragalus membranaceus, Hemerocallis citrina, caffeic acid, and resveratrol in targeting mitochondrial dysfunction in SCA3. These natural medicines were reported to regulate multiple mitochondrial-associated pathways, including oxidative stress, mitochondrial membrane potential, mitochondrial bioenergetics, mitochondrial dynamics, mitochondrial quality control, and mitochondria-mediated apoptosis, thereby improving neuronal survival and mitochondrial function in experimental SCA3 models. In conclusion, natural medicines targeting mitochondrial dysfunction represent promising preclinical candidates for further investigation in SCA3. However, further mechanistic investigations, well-designed clinical trials, and optimization of pharmacokinetic properties are required to facilitate their translation into clinical practice.

  • Accelerating Parkinson’s Disease Discovery: An in silico Zebrafish Predictive Model

    by Wael Mohamed, Mwafaq Kmail

    Parkinson’s Disease (PD) remains a major neurodegenerative disorder lacking disease-modifying therapies. Traditional single model approaches often fail to capture the complex molecular, environmental, and genetic interactions that drive disease heterogeneity. This narrative review focuses on the emerging paradigm of hybrid modeling, using zebrafish (Danio rerio) experimentation with in silico computational and AI-driven pipelines to advance PD research. Zebrafish provide a strong in vivo system to study dopaminergic neurodegeneration, mitochondrial dysfunction, oxidative stress, and behavioral phenotypes with high translational value. In parallel, computational neuroscience and systems biology tools, including network pharmacology, molecular docking, virtual screening, transcriptomic profiling, and machine-learning–based predictive models, enable rapid hypothesis generation and therapeutic discovery. By combining these two modalities, hybrid platforms help to understand of PD pathogenesis and allow effective identification of biomarkers, drug candidates, and gene–environment interactions. This review highlights the current evidence, methodological advances, challenges, and future directions for establishing zebrafish–in–silico hybrid pipelines as next-generation tools for PD precision research. Importantly, this review proposes an integrated framework that bridges in vivo zebrafish models with in silico and AI-driven approaches, offering a novel strategy to accelerate translational discovery in PD.